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Abstract
Purpose Pediatric Cushing’s disease (CD) is rare and there
are limited data on the long-term outcomes. We assessed
CD recurrence, body composition, pituitary function and
psychiatric comorbidity in a cohort of pediatric CD
patients.
Methods Retrospective review of 21 CD patients, mean
age at diagnosis 12.1 years (5.7–17.8), managed in our
center between 1986 and 2010. Mean follow-up from
definitive treatment was 10.6 years (2.9–27.2).
Results Fifteen patients were in remission following
transsphenoidal surgery (TSS) and 5 were in remission
following TSS ? external pituitary radiotherapy (RT). One
patient underwent bilateral adrenalectomy (BA). CD
recurrence occurred in 3 (14.3 %) patients: 2 at 2 and
6 years after TSS and 1 7.6 years post-RT. The BA patient
developed Nelson’s syndrome requiring pituitary RT 0.6
years post-surgery. Short-term growth hormone deficiency
(GHD) was present in 14 patients (81 % patients tested)
(11 following TSS and 3 after RT) and 4 (44 % of tested)
had long-term GHD. Gonadotropin deficiency caused
impaired pubertal development in 9 patients (43 %), 4
requiring sex steroid replacement post-puberty. Four
patients (19 %) had more than one pituitary hormone
deficiency, 3 after TSS and 1 post-RT. Five patients (24 %)
had long-term psychiatric co-morbidities (cognitive dys-
function or mood disturbance). There were significant
long-term improvements in growth, weight and bone den-
sity but not complete reversal to normal in all patients.
Conclusions The long-term consequences of the diagnosis
and treatment of CD in children is broadly similar to that
seen in adults, with recurrence of CD after successful
treatment uncommon but still seen. Pituitary hormone
deficiencies occurred in the majority of patients after
remission, and assessment and appropriate treatment of
GHD is essential. However, while many parameters
improve, some children may still have mild but persistent
defects.
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Introduction
Cushing’s disease (CD) is defined as hypercortisolism due
to excess pituitary ACTH secretion by a corticotroph
adenoma accounting for *75 % of cases of pediatric
Cushing’s syndrome [1]. The diagnostic and therapeutic
strategies are largely based on experience in the adult CD
population, although some differences in presentation and
responses to therapy exist [2]. Long-term consequences of
adult CD are well documented, including morbidity,
recurrence and its sequelae [3], but limited data exist for
pediatric patients after transsphenoidal surgery (TSS) and
external pituitary radiotherapy (RT).
Growth and body composition are frequently compro-
mised in pediatric CD at diagnosis, and following suc-
cessful therapy, height and weight may not normalize
[4, 5]. Early growth hormone treatment following remis-
sion of hypercortisolemia may improve catch-up growth
and adult height [4]. Abnormal puberty with virilization
and gonadotropin deficiency is recognized in CD [6].
Defects in pituitary function following remission of CD
after TSS or RT are well described [7–9]. Hypercorti-
solemia also affects mood and may precipitate psychiatric
disturbances, with uncertain long-term sequelae [3].
Due to the rarity of pediatric CD, only a few centers
have experience of its treatment and follow-up with few
published data on the long-term outcome following treat-
ment during childhood, with most reports only looking at
the short-term results. Differences in management proto-
cols and definitions of remission or ‘cure’ have led to rates
of successful treatment reported from 60 to 98 %
[1, 8, 10, 11]. Variation is also seen for rates of recurrence
after remission, ranging from 6 to 27 % [10, 12, 13]. We
have previously extensively described the presenting fea-
tures, diagnostic testing and early outcomes of children
with CD: we now describe the longer-term outcome in 21
pediatric CD patients, diagnosed and treated in one center,
concentrating on the prevalence of recurrence and features
of linear growth, body composition, pubertal development,
pituitary function and psychiatric status.
Patients and methods
Twenty-one patients (13 males) were diagnosed with CD
and treated at St. Bartholomew’s and The Royal London
Hospitals, London, UK, between 1986 and 2010 (Table 1).
Twelve patients were followed up at our center and 9 with
endocrinologists in other institutions. Data were retro-
spectively collected and therefore there was some missing
data. The mean length of follow-up from time of definitive
therapy, which resulted in remission in all cases, was
10.6 years (2.9–27.2).
Informed consent was obtained and Institutional Review
Board permission was granted for the release of anon-
ymized data for publication.
Definition of latest assessment
‘Latest assessment’ is defined as the time the individual
patient was assessed most recently. This corresponds to the
follow-up interval from definitive therapy (mean
10.6 years; range 2.9–27.2).
Clinical features at diagnosis
Mean age at presentation was 12.1 years (5.7–17.8). The
most common presenting features were weight gain
(100 %), change in facial appearance (100 %), growth
retardation (95 %). emotional lability (71 %) and fatigue
(62 %). Other features included hypertension (43 %), acne
(38 %), hirsutism (52 %), headaches (52 %) and striae
(43 %). Less common presenting features were acute
psychosis (Patient 1), hypokalemia (Patient 7), vertebral
fractures due to severe osteoporosis (Patient 14) and anx-
iety combined with challenging behavior (Patient 17).
Mean symptom duration prior to diagnosis was 1.8 years
(range 0.5–3.5) (Table 1). At diagnosis, 8 patients (4
males) were pubertal, i.e. testicular volume C4 ml or
breast stage C2 according to Tanner’s criteria [14, 15] and
13 (9 males) were prepubertal. All but 2 prepubertal
patients (1 male) showed signs of virilization with abnor-
mally advanced pubic hair growth or genital development
(Table 1). Hypertension in the pediatric and adult subjects
was defined as previously described [16, 17].
Diagnosis of CD
Diagnosis of CD was made on the basis of loss of cortisol
circadian rhythm, elevated sleeping midnight serum cortisol
[50 nmol/l, detectable plasma ACTH, failure to suppress
cortisol to \50 nmol/l during a low-dose dexamethasone
suppression test (LDDST) and exaggerated increase of
serum cortisol during a human-sequence corticotrophin-
releasing hormone (1 lg/kg IV CRH) test [1]. Suppression
of cortisol by [50 % during high-dose dexamethasone
suppression test (HDDST), also consistent with CD, was a
further feature [18].
Pituitary imaging
Magnetic resonance imaging (MRI) was performed at 1.5T
preoperatively in 20 patients as previously described [19].
One patient, investigated in 1986, had a pituitary CT scan
[19].
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Bilateral simultaneous inferior petrosal sinus
sampling for ACTH (BSIPSS)
BSIPSS was performed without general anesthetic or
sedation as previously described [18, 20]. Central ACTH
secretion was confirmed by an inferior petrosal sinus
(central) to peripheral ACTH ratio C3.0 (IPS/P) after
administration of 100 lg IV CRH. Lateralization of ACTH
secretion was defined as an inter-petrosal sinus ACTH
gradient (IPSG) of C1.4 [20].
Hormone assays
Serum cortisol, T4 (free and total), TSH, PRL, LH, FSH,
GH, ACTH and testosterone were determined as previously
described [19].
Auxology and puberty staging
Standardized anthropometric techniques were used to
measure height, weight and height velocity [21]. Target
height (TH; in cm) was calculated using the formula:
mother’s height ? father’s height ? 13 divided by 2 for
boys, mother’s height ? father’s height –13 divided by 2
for girls, and was expressed as SDS [4]. Adult height (AH)
was defined as height when measurements over 12 months
differed by\1 cm. BMI and height were converted to
standard deviation scores (SDS) as previously described
[22]. Pubertal development was staged according to the
criteria of Tanner and testicular volumes were measured
using a Prader orchidometer [14, 15].
Definitive therapy and remission of CD
Transsphenoidal pituitary exploration (TSS), aimed at
selective microadenomectomy, was performed in all
patients by two neurosurgeons, FA or IS. Biochemical
remission after TSS was defined as serum cortisol
\50 nmol/l on at least 3 mornings during the immediate
post-operative period [1]. Patients in whom post-operative
remission was not achieved (n = 5) had second-line ther-
apy with external pituitary irradiation (RT) [18]. Bio-
chemical remission following RT was defined as mean
serum cortisol\150 nmol/l on a 5-point day-curve and
midnight cortisol of\50 nmol/l [18]. The RT was deliv-
ered at a mean interval of 85.8 days (23–177) after
unsuccessful TSS. Recovery of serum cortisol post-TSS or
RT was defined as mean serum cortisol 150–300 nmol/l on
a 5-point day curve [18]. Post-operatively, patients with
cortisol \50 nmol/l were commenced on replacement
hydrocortisone therapy. The HPA axis was reassessed at
regular intervals for recovery as previously described [23].
Recurrence of CD and Nelson syndrome
Recurrence of CD was defined as the presence of bio-
chemical features of CD i.e. increased midnight sleeping
cortisol, lack of suppression of cortisol during LDDST and
increased 24 h urinary free cortisol values, which recurred
after definitive therapy that resulted in clinical remission.
Nelson syndrome was defined as enlarging pituitary corti-
cotropinoma with elevated and rising ACTH levels fol-
lowing bilateral adrenalectomy [24].
Assessment of GH secretion
GH secretion was assessed as follows: insulin tolerance test
(ITT, 0.15 U/kg insulin IV), glucagon stimulation
(15 mcg/kg IM) and arginine test (0.5 g/kg L-arginine
monohydrochloride IV). GH deficiency (GHD) was defined
as peak GH\7 lg/l during the stimulation test [4, 8]. GH
secretion was first assessed during remission following
definitive treatment of CD (short-term assessment) and
again after completion of linear growth (long-term
assessment). GHD in adolescents and adults was defined
according to consensus publications [25, 26].
Statistical analysis
Statistical analysis was performed using IBM SPSS
Statistics 23. The paired-samples T Test was used to
determine significant differences between height SDS,
BMI SDS, target height SDS and height SDS at diagnosis
and follow-up.
Results
Diagnostic investigations
Mean sleeping serum cortisol at midnight was 505.1 nmol/l
(142–1082) and 09.00 h ACTH 42.4 ng/l (13–96, normal
10–50). All patients had a LDDST and 18/21 (86 %)
showed inadequate cortisol suppression. HDDST was
performed in 12 (57 %) patients and 9/12 (75 %) sup-
pressed 09.00 h cortisol at 48 h to\50 nmol/l. The CRH
test was performed in all patients and induced a mean
cortisol increase of 90.5 %: in 19/21 (90 %), the cortisol
rise during the CRH test was[20 %.
MRI or CT scans of the hypothalamo-pituitary region
showed abnormalities consistent with a pituitary adenoma
in 9/21 (43 %). Concordance between the site of the ade-
noma on imaging and at surgery was 3/21 (14.3 %).
Nineteen (91 %) patients had BSIPSS, which showed lat-
eralization of ACTH secretion in 14 (73.7 %; 7 right, 7
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left): concordance between lateralization of the tumor on
BSIPSS and during surgery was 14/19 (74 %) with 87 %
(13/15) concordance in the remission patients vs 25 % (1/
4) in the non-remission patients. The results of the bio-
chemical and imaging investigations are shown in Tables 1
and 2.
Table 2 Details of pituitary imaging, BSIPSS, pituitary histology, definitive treatment and outcome
Pt
no.
BSIPSS MRI/
CT
Adenoma
position at
TSS
Pituitary
histology
09.00 h
Cortisol
nmol/L
post-
TSS
(day)
Definitive
treatment
Interval
(yrs) to
post-RT
remission
Time of
recovery of
pituitary-
adrenal axis
(yr) post-TSS
or RT
Time of
recurrence
(yrs) post-
definitive
treatment
Long-term
outcome
1 ML R R N 719 (7) TSSa ? TSS ? BA – – No Nelson’s syndrome
(0.6 years post
BA)
2 – ML N (biopsy) N 269 (10) TSS ? RT 0.9 1.2 No Remission
3 – ML R Adenoma 630 (4) TSS ? RT 0.3 1.1 No Remission
4 L N R N 600 (5) TSS ? RT 0.1 0.4 Yes (7.6) Abnormal cortisol
circadian
rhythm—no
treatment
5 ML L L N 612 (6) TSS ? RT 0.4 0.6 No Remission
6 L N L N 382 (8) TSS ? RT 2.2 – No BA for ACTH-
independent
cortisol secretion
(3.9 years post-
RT)—remission
7 L ML/
R
ML N 43 (5) TSS – – Yes (2.0) TSS—no
remission, RT—
remission
(1.4 years post
RT)
8 R N R Adenoma \50 (4) TSS – No recovery No Remission
9 L R L Adenoma \50 (3) TSS – 12.0 No Remission
10 R N R Adenoma \50 (6) TSS – – No Remission
11 R N R N \50 (5) TSS – Yes No Remission
12 L R L N \50 (5) TSSa ? TSS – 1.8 No Remission
13 ML L ML/R N \50 (6) TSS – 0.7 No Remission
14 R N R Adenoma \50 (2) TSS – 2.3 No Remission
15 L ML ML Adenoma \50 (2) TSS – – Yes (6.0) RT—no remission,
metyrapone—no
remission,
pasireotide-
remission
(3.0 years post
RT)
16 Lb N L Adenoma 36 (8) TSS – 1.7 No Remission
17 Rb N R Adenoma 22 (5) TSS – – No Remission
18 R N R Adenoma 44 (5) TSS – 2.1 No Remission
19 ML N ML Adenoma \50 (7) TSS – 4.0 No Remission
20 R N R Adenoma 20 (4) TSS – 1.45 No Remission
21 ML N Diffuse
adenoma
Adenoma 21 (5) TSS – No recovery No Remission
BSIPSS bilateral simultaneous inferior petrosal sinus sampling, IPS/P interpetrosal sinus ACTH gradient (C1.4 suggests lateralisation) (2), L left-
sided lateralisation/adenoma position, R right-sided lateralisation/adenoma position (bperformed under general anesthesia); ML no lateralisation/
midline position, N normal, TSS transsphenoidal surgery (aperformed at another centre), RT external beam pituitary radiotherapy, BA bilateral
adrenalectomy
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Transsphenoidal surgery (TSS)
Transnasal endoscopic TSS (performed by surgeons IS,
GA) was undertaken in 3 patients (Patients 17, 21 and the
second procedure for Patient 14). A translabial transsphe-
noidal approach was used in the remaining surgical pro-
cedures (performed by surgeon FA). 14 patients (67 %)
had biochemical remission after a single TSS procedure
and one patient after two consecutive TSS procedures
(Patient 12), the first being performed at another center.
The overall rate of remission following TSS in our center
was 71 %.
Five patients (Patients 2–6; 24 %) had elevated cortisol
post-operatively with values ranging from 269 to
900 nmol/l (mean 478 nmol/l) indicating lack of remission.
In all cases, remission was achieved following second-line
RT, with a mean interval between RT and remission of
0.8 years (0.1–2.2). Patient 1 who had two consecutive
unsuccessful TSS procedures underwent bilateral
adrenalectomy (BA) because of severe, acute psychosis
[27]. Details of the treatment modalities are shown in
Table 2.
Pituitary histology
In 20/21 (95 %) patients a pituitary microadenoma was
identified at surgery, in all patients in remission after a
single TSS procedure, and in 4/5 (80 %) in whom TSS was
unsuccessful (Table 2). In 12/21 (57 %) patients, positive
histology confirmed a corticotrope adenoma. Positive his-
tology was present in 11/15 (73 %) patients with post-op-
erative remission and 1/6 (17 %) patients without
remission (Table 2).
Recurrence rates and management
Clinical and biochemical recurrence of hypercortisolemia
was seen in 2 patients (Patients 7 and 15) (10 %) and mild
biochemical abnormalities, suggestive of subclinical
recurrence, in Patient 4 (Table 2). The features in Patient 7
were weight gain and growth arrest, increased midnight
cortisol and MRI evidence of a microadenoma, but normal
cortisol suppression during LDDST 2.0 years after initial
remission. A second TSS was unsuccessful, but biochem-
ical remission was achieved 1.4 years after pituitary RT.
Patient 15 relapsed 6 years after successful TSS, and sub-
sequent RT failed to induce remission. The patient refused
bilateral adrenalectomy and is being managed with pasir-
eotide, which is controlling the hypercortisolemia. Patient
4 had consistently raised midnight cortisol 7.6 years after
RT. There were no signs of hypercortisolemia and LDDST
showed adequate cortisol suppression. This patient is on no
treatment with no progression for 10 years.
Other complications of definitive treatment
Patient 6 developed autonomous (ACTH-independent)
adrenal cortisol secretion following TSS ? RT (3.9 years
post-RT) and was cured following bilateral adrenalectomy.
At 1.5 years post-adrenalectomy, he had normal ACTH
secretion and no evidence of a pituitary adenoma on pitu-
itary MRI. Patient 1 had elevated and increasing ACTH
(333 ng/L, normal 10–50) associated with MRI enlarge-
ment of the pituitary adenoma (3–7 mm diameter) and
underwent pituitary radiotherapy 0.6 years following
bilateral adrenalectomy. The ACTH increased to 1253 ng/
L approximately 0.5 years after completion of RT. At latest
assessment, 2.5 years post-RT, the adenoma measures
8.2 mm and ACTH is 373 ng/L.
Anterior and posterior pituitary function
GH secretion
Short-term GH assessment of was performed in 19 patients
at a mean interval of 0.5 years (0.1–1.4) after the last
definitive treatment for CD, TSS (n = 15 patients) and RT
(n = 4 patients) (mean peak GH 6.4 lg/l, range\
0.5–18.3). GHD was present in 14/19 (81 %) (mean peak
GH 3.1 lg/l, range\ 0.5–6.9), 79 % after TSS and 21.5 %
after RT (Table 3). GH therapy was administered in 14
patients (77.8 % of all tested), 11 (73 %) after TSS and 3
(75 %) after RT, and continued in 12 until adult or near-
adult height.
Long-term GH assessment was performed in 9 patients
at a mean interval of 8.5 years (3.8–17.0) after the last
definitive treatment, TSS (n = 6 patients) and RT (n = 3
patients) (mean peak GH 6.4 lg/l, range 0.4–19.4). Long-
term GHD (mean peak GH 0.7 lg/l, range 0.4–0.9) was
present in 4/9 investigated (44 % of all tested): 67 % after
TSS and 33 % after RT (Table 3). GH therapy was con-
tinued in patient 14 who had GHD post-TSS and has
completed his linear growth. This patient has not been
retested for GHD but presented with vertebral fractures and
GH therapy is on-going until he achieves peak bone mass.
Gonadotropin secretion
At latest assessment, 14 patients (8 males; 66.7 %) had
completed and 7 patients (5 males; 33.3 %) were under-
going pubertal development. Nine patients (7 males;
42.9 %) had delayed onset or slow progression of puberty.
Six required hormonal replacement (Table 4). Five males
received testosterone or FSH ? HCG therapy (Patients 5,
8, 12, 14, 21). Four (19 %) (Patients 1, 14, 15, 21) had
evidence of long-term hypogonadotropic hypogonadism
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requiring replacement therapy as adults. Three female
patients have had children (Table 4).
TSH secretion
TSH deficiency was seen in 2 patients (9.5 %). Both had a
single TSS procedure (Patients 8, 21) and had associated
pituitary hormone deficiencies (Table 4).
ACTH secretion
The mean time interval between recovery of the pituitary-
adrenal axis following TSS (8 patients) was 3.2 years
(0.7–12.0 years), and following RT (4 patients) 0.8 years
(0.4–1.2 years). At latest assessment, 2 patients (9.5 %)
had persistent ACTH deficiency (Patients 8, 21) requiring
daily hydrocortisone replacement therapy (Table 4): both
had one TSS procedure and had additional anterior pitu-
itary defects.
AVP secretion
Seven patients (33.3 %) developed central diabetes insi-
pidus (DI) post-TSS. AVP secretion recovered in 5/7
(71.4 %) patients, 4 in the immediate postoperative period.
One patient required desmopressin therapy for 6 years.
Two patients (10 %) had permanent DI associated with
additional anterior pituitary defects.
Table 3 Short- and long-term assessment of growth hormone secretion and growth hormone treatment
Short -term assessment Long-term assessment
Pt
no.
Definitive
treatment
Time
interval
(yr)
GH test GH
peak
(lg/l)
GHD GH treatment GH
treatment
(yr)
Other CD
treat-ment
GH test GH
peak
(lg/l)
Time
interval
(yr)
GHD
1 2
TSS ? BA
– – – – No – RT – – – –
2 TSS ? RT 0.7 Glucagon 6.9 Yes Yes 8.0 (AH) – ITT 5.7 9.6 No
3 TSS ? RT 0.7 Glucagon 6.4 Yes Yes 3.5 (AH) – ITT 11.4 8.6 No
4 TSS ? RT 1.4 ITT 16.5 No Yes 1.8 (AH) – ITT 19.4 7.6 No
5 TSS ? RT 0.3 ITT \1.0 Yes Yes 7.1 (AH) – – – – –
6 TSS ? RT – – – – No – BA – – – –
7 TSS 0.2 ITT 12 No Yes
(?Letrozole)
1.5 (AH) TSS ? RT – – – –
8 TSS 0.7 Arginine 1.1 Yes Yes 9.9 (LA) – ITT 0.9 10.0 Yes
9 TSS 0.7 ITT 18.3 No No – – – – – –
10 TSS – ITT 3.8 Yes Yes – – ITT 10.1 17.0 No
11 TSS 0.2 ITT 4.0 Yes Yes 7.7 (AH) – ITT 8.2 8.1 No
12 2 TSS 0.2 ITT \0.5 Yes Yes 10.7 (AH) – ITT 0.4 7.5 Yes
13 TSS 0.1 ITT 5.5 Yes No – – – – – –
14 TSS 0.1 ITT 3.5 Yes Yes 12.5 (AH/
LA)a
– – – – –
15 TSS – – – Yes Yes – RT – – – –
16 TSS 0.3 Glucagon 16.1 No Yes 3.4 (LA) – Glucagon 0.4 3.8 Yes
17 TSS 0.8 Glucagon 9.5 No No – – – – – –
18 TSS 0.5 ITT 2.6 Yes Yes 1.6 (AH) – – – – –
19 TSS 0.8 ITT 1.6 Yes Yes
(?GnRHa)
3.4 – ITT 0.9 4.6 Yes
20 TSS 0.5 Glucagon 5.3 Yes No – – – – – –
21 TSS 0.9 ITT 0.6 Yes Yes 4.3 (LA) – – – – –
TSS transsphenoidal surgery, 2 TSS two surgical procedures undertaken (see Table 2), RT external beam pituitary radiotherapy, BA bilateral
adrenalectomy, Time interval time interval between the last definitive treatment inducing remission and GH testing, ITT insulin tolerance test,
Time interval the interval between definitive treatment and GH testing, GnRHa gonadotrophin releasing hormone analogue, AH adult height, LA
latest assessment
a GH therapy ongoing until peak bone mass achieved
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Long-term multiple versus single pituitary hormone
deficiencies
At latest assessment, 5 patients had a single pituitary
hormone deficiency. GHD was the most frequent isolated
long-term deficiency, occurring in 4 (19.0 %) and gona-
dotropin deficiency in 1 (5 %) (Table 3). Four patients
had more than one anterior pituitary hormone deficiency
(19 %) 3 after TSS (Patients 8, 14 and 21) and 1
following RT (Patient 15) (Table 4). Patient 8 had GH,
gonadotropin, TSH,ACTH and prolactin deficiencies.
Patient number 21 had GH, TSH, gonadotropin, ACTH,
prolactin and AVP deficiencies. Patient number 14 had
gonadotropin and GH deficiencies and patient 15 had
gonadotropin and AVP deficiencies. Therefore, in total,
43 % patients had long-term pituitary deficiencies but
only 5 of these (24 % of the whole cohort) receive on-
going replacement therapies.
Table 4 Anterior and posterior pituitary hormone deficiencies following treatment for paediatric CD
Pt
no.
CD Therapies Puberty features Pubertal
induction
Additional long-term pituitary deficiencies
Gonadotrophin AVP TSH ACTH PRL Other features
1 2 TSS ? BA,
RT
Slow progression, late
menarche at 16.0 years and
poor breast development.
? (Oral
oestrogen for
0.6 years)
? (HRT since
aged
20 years)
– – – – Breast
Augmentation
aged 17 years
2 TSS ? RT no – – – – –
3 TSS ? RT no – – – – – –
4 TSS ? RT – – – – – – –
5 TSS ? RT Slow progression ? (Testosterone
for 2.3 years)
– – – – –
6 TSS ? RT,
BA
Slow progression – – – – –
7 2TSS ? RT Slow progression – – – – – – Poor semen
quality aged
17 years
8 TSS Delayed and slow progression ? (Testosterone
for 1.2 years)
– – ? ? ?
9 TSS – – – – – – PCOS 3 children
10 TSS – – – – – – HRT aged 37
years 3
children
11 TSS Late menarche (17.6 years) – – – – – – Low libido 1
child
12 2TSS Delayed onset ? (Testosterone
for 0.3 years)
– – – – –
13 TSS – – – – – – –
14 TSS Pubertal arrest ? Testosterone
since aged
16years
? – – –
15 TSS ? RT – – ? ? – –
16 TSS – – – – – –
17 TSS – – – – – –
18 TSS – – – – – – High
(737,
rr
0–496)
19 TSS – – – – – –
20 TSS – – – – – – –
21 TSS (diffuse
tumour)
HH ? (HCG, FSH) ? (Testogel) ? ? ? ? Normal semen
analysis
HH hypogonadotropic hypogonadism, ? deficiency present, - deficiency absent, AVP vasopressin, TSH thyroid stimulating hormone deficiency,
ACTH adrenocorticotropin deficiency, PRL prolactin deficiency
Pituitary (2016) 19:612–624 619
123
Linear growth
At diagnosis, mean height SDS for the whole cohort was
-1.5 (0.1 to -3.3). Mean height SDS at diagnosis for the
15 patients with FU height data was -1.6 (0.1 to -3.3) and
the height SDS at adult height (AH) (n = 8) or latest
assessment (LA) (n = 7) was mean -0.99 (0.46 to -2.84)
at a mean 6.7 years (2.6–16.6) post-definitive therapy and
7.1 years (2.7–17.3) post-diagnosis. Therefore, height SDS
at follow-up (AH or LA) had increased compared to
diagnosis (mean change ?0.60; range -0.79–2.90 SDS)
(p = 0.033) (Fig. 1).
Mean target height (TH) SDS for the 15 patients with
follow-up data was ?0.03 (-1.83–1.91) and differed from
the height SDS at diagnosis and AH or LA (p = 0.000)
(Fig. 1). The difference between TH and AH/LA SDS
(mean 1.01; range -0.17–2.44) was less than the difference
between TH SDS and height SDS at diagnosis (1.61; range
0.22–3.4) (p = 0.033).
BMI
BMI SDS (n = 15) was lower at LA (mean 0.58;
-1.9–2.71), compared to diagnosis mean BMI SDS 2.9
(0.1–6.9) (p = 0.000) (Fig. 2). The interval between
definitive therapy and BMI LA was 6.7 years (range
2.6–16.6).
Bone Mineral Density (BMD)
At diagnosis, 10 patients had BMD assessed by DEXA
scan. L1-L4 areal BMD Z scores in 5 patients were mean
-1.3 (-0.3 to -2.6) and mean L2-L4 areal BMD Z scores
in 5 patients were -2.0 (-0.6 to -3.3). In 3/10 patients,
femoral neck BMD was mean -1.7 (-1.0 to -2.1). The
BMD Z-score at diagnosis was\-2 in 30 % of patients,
-2 to \-1 in 50 % and -1 to\0 in 20 % patients. No
patient had a BMD Z-score above 0.
Nine patients had follow-up (mean 5.2 years; 1.4–10.5) L2-
L4 areal BMD mean Z score -0.5 (1.1 to -2.0). Mean areal
femoral neck BMD Z score (5 patients) was 0.22 (2.46 to-0.9)
after a mean follow-up interval of 5.83 years (1.4–10.5). The
BMD Z-score at follow-up was\-2 in 20 % of patients,-2
to\-1 in 20 %,-1 to\0 in 20 % and 0–2 in 40 % patients.
Patients with lowest Z-score values at diagnosis were Patients
7 (L1-L4 BMD Z-score -2.6) and 14 who presented with
vertebral fractures (L2-L4 aBMD Z-score-3.3) and Patient 18
(L2-L4 aBMD Z-score -3.0). These improved to -1.8, -2.0
and -1.0 at 1.8, 2.0 and 10 years, respectively.
Blood pressure
At diagnosis, 9 (43 %) patients had hypertension. Blood
pressure data were available in 9 patients at latest assess-
ment. Three (33.3 %), had hypertension at a mean age
Fig. 1 Height SDS at
diagnosis, latest assessment and
target height SDS (n = 15).
Boxplot graph of the 15 patients
with follow-up and target height
growth data. Box, interquartile
range (lower quartile, median
and upper quartile); whiskers,
maximum and minimum values;
outliers represented with circle
and patient number.
*p = 0.033, **p = 0.000
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32.4 years (23.7–44.0), but were not prescribed antihy-
pertensive medications.
Psychiatric and cognitive problems
In total, 5 patients (24 %) had long-term psychiatric co-mor-
bidities. Patient 17 had anxiety with challenging behavior.
Patient 1 developed acute psychosis with self-injuries [27].
After resolution of the hypercortisolemia following bilateral
adrenalectomy, the psychotic episode (and the associated
cerebral volume loss on radiological imaging) resolved. She
had prolonged hypercortisolemia before remission with social
problems and low self-esteem. Following remission, she
developed clinical depression treated with fluoxetine. Her
symptoms improved after breast augmentation surgery and
she is currently off anti-depressant therapy.
Three patients (14 %) reported problems with memory.
Patient 4 had TSS ? RT and reported transient problems
with concentration following RT, but subsequently made
good academic progress. Patient 5 (after RT) and Patient
21 (after TSS) had decreased short-term memory and
concentration, causing impaired school performance.
Patient 2 had occasional post-treatment mood swings.
Discussion
CD is rare in childhood and a limited number of centers
have the capacity to manage this condition comprehen-
sively. Close collaboration with adult colleagues with
experience of CD is beneficial for pediatric management
[1]. The presenting features may differ in children com-
pared to adults, with growth arrest and rapid weight gain
being the main presenting features [1]. The signs and
symptoms at diagnosis in our cohort of patients are con-
sistent with reports from other centers [10, 13].
Transsphenoidal surgery, performed by pituitary sur-
geons with experience in children, is effective and safe
first-line treatment [1, 10]. Reported rates of remission
after TSS vary from 60 to 98 % in different studies [1], due
largely to the lack of agreement on definition of post-op-
erative remission. In all reports of pituitary surgery, a
proportion of patients do not achieve biochemical remis-
sion and this was also the case in our series.
Identification of the corticotrope adenoma during sur-
gery and its histological confirmation are positive predic-
tors of remission [10, 13, 23, 28]. Our series confirmed this
observation, with an adenoma identified during surgery in
all patients in remission after TSS. One factor reported to
be associated with a higher prevalence of recurrence of CD
is a younger age (\20 years) at diagnosis [10, 12]. We
found no association between recurrence and age. Patients
in whom CD recurred had a shorter mean duration of
symptoms, i.e. 0.9 years, compared with 1.9 years in sub-
jects remaining in remission. There was no relationship
between severity of clinical symptoms or biochemical
abnormalities and recurrence.
Recurrence rates after remission of pediatric CD vary
considerably from 8 % to [ 40 % [10–12]. Even though
relapse is usually expected during the first 5 years
Fig. 2 BMI SDS at diagnosis
and follow-up (n = 15) Boxplot
graph of the 15 patients with
follow-up BMI data: box,
interquartile range (lower
quartile, median and upper
quartile); whiskers, maximum
and minimum values; outliers
represented with circle and
patient number. *p = 0.000
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following definitive treatment, it may occur later [29] and
the percentage of relapsed cases increases with length of
observation [23]. In our series, mean follow-up was more
than 10 years. We report a small but important prevalence
of recurrence, demonstrating that life-long follow-up is
required, and this is consistent with data from long-term
follow-up in adult patients with CD (24).
Following successful TSS, most patients showed
recovery of the pituitary-adrenal axis. Similar results were
reported by Devoe et al. [8]. Time to recovery of the axis
has been considered to be a predictive factor for CD
recurrence in adults and in children [10, 13, 23]. Unfortu-
nately, in our series data for recovery of the axis were not
complete in the patients with recurrence; however, no
patient in remission after TSS had recovery of the axis at
less than 0.65 years after pituitary surgery.
At final evaluation, single pituitary hormone deficien-
cies were seen in 5 patients (24 %). Most common was GH
deficiency (GHD), which is well-recognized following TSS
[30] and pituitary irradiation [9, 18]. Additional pituitary
deficiencies were rare. When these occurred they were
associated with other anterior and posterior pituitary
defects. The percentage of endocrine deficits in our series
is higher than reported in other pediatric CD studies [8, 31].
The reason for this is unclear, but may be due to the fact
that these patients have more active on-going surveillance.
Growth is frequently compromised in pediatric CD
[1, 4, 32]. Even after successful treatment, children often did
not attain the required catch-up growth to reach their target
height and adult height was subnormal [32]. Following TSS
and radiotherapy, GHD is frequently present [8, 32]. In our
series, short-term GHD was seen in the majority of tested
subjects, but following long-term retesting, GH secretion
had recovered in a significant proportion of patients (71 %).
Experience in our center has shown that hGH therapy can
benefit children with suboptimal post-remission catch-up
growth. Our advice, for early GH testing and initiation of
hGH therapy when indicated, has recently been endorsed
[5]. Vertebral bone mineral density (BMD) is more severely
affected than femoral BMD in children with CD and is
independent of the degree or duration of hypercortisolism
[33]. In our series, mean lumbar spine BMD was reduced at
diagnosis and improved at follow-up. Complete reversal to
normal bone mass was not seen in all patients, suggesting
some individuals may be at future risk of osteopenia.
Pubertal development is disturbed in many patients
presenting with CD [1, 6]. In our study many subjects had
disturbed timing or progression through puberty requiring
sex steroid replacement due to the suppressive effect of
hypercortisolemia on gonadotropins [6]. Close follow-up
of pubertal development and early identification of pitu-
itary–gonadal axis deficiency following remission of
pediatric CD is important.
BMI is expected to decrease in patients with biochem-
ical remission after definitive therapy, but may not
decrease to normal values [4, 34] with persistence of
central obesity [35]. In our series, mean BMI SDS
decreased significantly during remission towards normal-
ization in longer observation periods.
Psychological problems have been recognized with
long-standing hypercortisolemia in the pediatric age range
[36]. Many of our patients had emotional lability and
fatigue at diagnosis, and two had more severe problems. In
adults following treatment for CD, it is expected that
psychiatric symptoms would resolve, although some dis-
turbances might persist after cure [37]. The more severe
psychiatric and behavioral symptoms at diagnosis
improved significantly after cure. Hypercortisolemia may
induce atrophic changes in the CNS, with volume loss in
the temporal lobe, amygdala and the hippocampus [38, 39].
These effects might contribute to the behavioral and cog-
nitive changes seen in adult and pediatric CS patients [39].
One small pediatric study reports declining cognitive
function 1 year after cure of CS even after regaining lost
brain volume [36]. In our series, 3 patients reported cog-
nitive problems after treatment for CD, mostly with short-
term memory.
In experienced hands, the prognosis for pediatric CD is
good with various therapeutic options available, ranging
from transsphenoidal microadenomectomy to bilateral
adrenalectomy. As the majority of corticotrope adenomas
in children and adolescents are microadenomas, optimal
surgical care consists of tumor resection with maintenance
of pituitary tissue. Our current long-term experience indi-
cates that the diagnostic assessment and management of
children with CD is broadly similar to that seen in adult
patients, but growth is an important additional parameter,
which must be assessed and treated appropriately. GHD
can be managed with hGH replacement. There are long-
term improvements in growth, weight, bone density and
mental state, although in many cases they may not return
entirely to normal. Recurrence of hypercortisolemia fol-
lowing successful post-TSS or post-RT-induced remission
is unusual, but does occur as is also seen in adults. In our
series, no key factors predictive of recurrence were iden-
tified. There are clear indications that life-long endocrine
surveillance of pediatric patients, in whom remission has
been induced by pituitary surgery or radiotherapy, remains
mandatory.
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